Bremelanotide PT 141 CAS No.189691-06-3 CAS NO.189691-06-3

Min.Order Quantity:: 1 Gram

Purity:: 98%MIN

Port:: Ningbo/Shanghai port/other ports

Payment Terms:: L/C,D/P,T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

Bromelanotide
cas 189691-06-3
PT-141

Quick Details

ProName: Bremelanotide PT 141 CAS No.189691-06-...
CasNo: 189691-06-3
Molecular Formula: C50H68N14O10
Appearance: white powder
Application: Pharmaceutical Intermediates
DeliveryTime: ASAP
PackAge: as your requests
Port: Ningbo/Shanghai port/other ports
ProductionCapacity: 1000 Kilogram/Month
Purity: 98%MIN
Transportation: The product will be sent out as soon a...
LimitNum: 1 Gram

Superiority

jinlan pharm-drugs technology co.,limited (with its export company hangzhou royall import & export co.,ltd.)is located in hangzhou, zhejiang province. neighboring ningbo port, shanghai port, hangzhou xiaoshan int’l airport and shanghai pudong int’l airport, the transportation and production environment are excellent. jinlan pharma is mainly engaged in r&d, manufacturing and marketing pharmaceuticals, chemical intermediates, biochemicals, veterinary medicines and nutrition products.

with its strong ability in r&d, and world-leading process technology, jinlan pharma develops the new and high-tech chemicals and pharmaceuticals. synthesis capacity from gram scale, kg scale to mt scale is available.

Details

bremelanotide pt 141 189691-06-3 professional supplier

specification:

bremelanotide // pt141

cas 189691-06-3

mf c50h68n14o10

mw 1025.2 g/mol

absrtact bremelanotide (formerly pt-141) is a compound under drug development by palatin technologies as a treatment for female sexual dysfunction, hemorrhagic shock and reperfusion injury. it functions by activating the melanocortin receptors mc1r and mc4r, to modulate inflammation and limitingischemia. it was originally tested for intranasal administration in treating female sexual dysfunctionbut this application was temporarily discontinued in 2008 after concerns were raised over adverse side effects of increased blood pressure. as of march, 2012, palatin is conducting a human phase 2b study using a new subcutaneous drug delivery system that appears to have little effect on blood pressure.